Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
A rapid increase in the female-to-male ratio of MS incidence has been observed through several population studies.
MULTIPLE SCLEROSIS ADVISOR
Multiple Sclerosis Advisor
Features
-
-
Stem Cell Therapy for Multiple Sclerosis: Addressing Patient Curiosity
Companies touting these therapies may use impressive websites with endorsements by celebrities and physicians to instill a sense that the procedures are safe and acceptable. -
Reproductive Management in Multiple Sclerosis: Quick Takeaways for Your Practice
While it is now well-established that having MS should not limit patients’ reproductive choices, this was not always the case. -
Cannabis for Multiple Sclerosis: Prescriber’s Perspective
Cannabis has been shown to reduce the use of prescription drugs that have more numerous and serious side effects, including opioids, benzodiazepines, and antidepressants. -
Dietary Supplements in MS: Exercising Caution With OTC Remedies
Until more robust studies are completed, clinicians should encourage a dialogue with their patients to discuss the use of and questions regarding over-the-counter supplements and alternative medicines.
Journal Articles
Bajrami A, Pitteri M, Castellaro M, et al. The effect of fingolimod on focal and diffuse grey matter damage in active MS patients
[published online June 25, 2018]. J Neurol. doi: 10.1007/s00415-018-8952-2
[published online June 25, 2018]. J Neurol. doi: 10.1007/s00415-018-8952-2
Mowry EM, Hedström AK, Gianfrancesco MA, et al. Incorporating machine learning approaches to assess putative environmental risk factors for multiple sclerosis.
Mult Scler Relat Disord. 2018; 24:135-141.
Mult Scler Relat Disord. 2018; 24:135-141.
Bensi C, Marrodan M, González A, et al. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
Mult Scler Relat Disord. 2018; 5:246-250.
Mult Scler Relat Disord. 2018; 5:246-250.
Brownlee WJ, Miszkiel KA, Tur C, Barkhof F, Miller DH, Ciccarelli O. Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis
[Published online August 17,2018]. Neurology. doi: 10.1212/WNL.0000000000006207
[Published online August 17,2018]. Neurology. doi: 10.1212/WNL.0000000000006207
Fakih R, Matiello M, Chitnis T, Stankiewicz JM. Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients
[published online September 10, 2018]. J Neurol. doi: 10.1007/s00415-018-9050-1
[published online September 10, 2018]. J Neurol. doi: 10.1007/s00415-018-9050-1
Patient Education Materials
- https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/Brochure-At-Home-with-MS%E2%80%94Adapting-Your-Environment.pdf
- https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/Brochure-Managing-MS-Through-Rehabilitation.pdf
- https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/Brochure-Just-the-Facts.pdf
- https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/Brochure-Driving-with-Multiple-Sclerosis.pdf
- https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/Brochure-The-MS-Disease-Modifying-Medications.pdf
Want to read more?
Please login or register first to view this content.
Next post in Multiple Sclerosis Advisor
